Cancer cells make blood vessels drug resistant during chemotherapy

Pinterest LinkedIn Tumblr +

Scientists at Hokkaido University, Japan, and collaborators have identified how inflammatory changes in tumours caused by chemotherapy trigger blood vessel anomalies and thus drug-resistance, resulting in poor prognosis of cancer patients.

Through mice experiments, the team also found that the combined usage of an inhibitor and anticancer drug makes chemotherapy more effective.

The study was published in Cancer Research, an AACR publication.

Chemotherapy is often chosen for treating inoperable cancers, such as locally advanced and metastasis cases.

It is, therefore, essential to unravel drug-resistance in this treatment, which has been a major factor in making cancer malignant and causing metastasis.

Tumour blood vessels play a key role in cancer progression because they carry nutrients and oxygen to tumours and serve as pathways for metastasis.

It had been generally believed that tumour endothelial cells (TEC) lining tumour blood vessels did not acquire drug-resistance.

However, several years ago, the group’s mice experiments showed TEC can obtain various anomalies, suggesting blood vessels, as well as cancer cells, can contribute to making tumours drug-resistant.

For example, the group demonstrated for the first time that TEC in blood vessels resist paclitaxel – a chemotherapy medication used for second-line treatment of urothelial cancer – due to the expression of ABCB1 which pumps out the drug from blood vessels.

However, much remains unknown about how human blood vessels are involved in cancer acquiring drug-resistance.

To help unravel this mystery, the group first analysed tumour tissue samples from urothelial cancer patients before and after they underwent first-line chemotherapy.

They found ABCB1 expression was increased in TEC in blood vessels of more than 60 percent of patients who received chemotherapy, and that their prognoses were poorer than patients whose ABCB1 expression remained the same after the treatment.

In addition, they analysed TEC in blood vessels and bladder cancer cells to study how chemotherapy affects ABCB1 expression.

The results showed that the increased secretion of interleukin-8 (IL-8) in cancer cells after chemotherapy caused inflammatory changes, increasing the ABCB1 expression in TEC.

In another experiment, mice with urothelial cancer administered with the ABCB1 inhibitor together with paclitaxel showed suppressed formation of new blood vessels and thus metastasis to the lung.

“Our study provides evidence, for the first time in humans, that inflammatory changes in tumours can cause drug resistance in cancer blood vessels,” says Kyoko Hida of Hokkaido University who led the group. “These findings could help devise new treatment strategies, such as the development of inhibitors targeting ABCB1 and IL-8, to suppress drug resistance and improve prognosis.”

Source: Hokkaido University


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.